Drug research

Sham

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity has not yet been verified against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
CardiAMP™ Cell Therapy for Heart Failure TrialNCT02438306	BCDA	Phase 3	Completed	2025-02Actual
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)NCT04757610	Opthea Limited	Phase 3	Terminated	2025-03-31Actual
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)NCT04757636	Opthea Limited	Phase 3	Terminated	2025-03-31Actual

BCDACompletedPrimary completion: 2025-02 · Actual

Trial details

Opthea LimitedTerminatedPrimary completion: 2025-03-31 · Actual

Trial details

Opthea LimitedTerminatedPrimary completion: 2025-03-31 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.